HSBC downgraded Hutchmed (HCM) to Hold from Buy with a $14.70 price target
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCM:
- Hutchmed says NDA for Tazverik granted conditional approval in China
- HUTCHMED’s Strong Financial Performance and Strategic Growth Drive Buy Rating
- Hutchmed Reports Strong 2024 Growth and Profitability
- Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M
- Hutchmed reports FY24 EPS 22c vs. 59c last year